Fig. 6: Combination of anlotinib and eribulin inhibited RLPS growth in vivo. | Cell Death Discovery

Fig. 6: Combination of anlotinib and eribulin inhibited RLPS growth in vivo.

From: Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress

Fig. 6

A Tumor growth curves for anlotinib, eribulin, combination, and control group. Values represented as mean ± SEM (n = 5), # compared to eribulin group with corresponding concentration, ## p < 0.01; ### p < 0.001. B Body weight measurement for each group. n.s. non-significant. C Representative HE staining of major vital organs, no obvious changes can be observed. Scale bar: 200 μm. D Western blots demonstrating anlotinib diminished RTKs and PD-L1 overexpression induced by eribulin. E CHOP, as a critical ERS regulator, was upregulated in the combination group compared with the eribulin group.

Back to article page